FIGURE 3.

BTK inhibition modifies CD14+ circulating monocytes in CLL patients and healthy donor. (A) CD14+ monocytes were pre-treated with ibrutinib for 1 h and stimulated with zymosan. Bar diagrams show the secretion of TNF-α by CD14+ circulating population in CLL patients measured by CSA (n = 6, *P < 0.05, **P < 0.01). (B) CD14+ monocytes were pre-treated with acalabrutinib for 1 h and stimulated with zymosan. Bar diagrams show the secretion of TNF-α by CD14+ circulating population in CLL patients measured by CSA (n = 8, **P < 0.01). (C) Dot plots show the amount of TNF-α secretion in CD14+ monocytes in healthy donor volunteers. Ibrutinib and acalabrutinib strongly affected the level of TNF-α either in presence or absence of zymosan stimulation (n = 7, *P < 0.05, **P < 0.01).